The ability of two S,S'-(alkane-l,(o-diyl) bisisothiouronium dibromides, three N,N'-(alkane-l,(u-diyl) bis guanidinium dinitrates and Ν,Ν'-bis (3-guanidinopropyl)piperazine dinitrate to inhibit constitutive (i. e. endothelial and neuronal forms) and inducible forms of nitric oxide synthases has been evaluated in vivo. These compounds, synthesized by two of us (J. C. L. and C. S.), have been tested in vivo; they were administered simultaneously with an irritant (carrageenan λ) into the pleural cavity. The amount of nitrites collected 0.5 and 7 hours after this injection can be considered as an indicator of nitric oxide (NO) production. According to previous data, the first harvesting time can be related to activation of constitutive NO synthases and the second to activation of inducible NO synthases.
Introduction
Nitric oxide (NO), a small membrane permeable gas, is enzymatically formed from a terminal guanidino nitrogen of L-arginine (1) by a family of three distinct NO synthase isoenzymes (2) and plays several physiological roles (3) . In this way, enhanced formation of NO following the induction of a distinct isoform of inducible NO synthase has been implicated in the pathogenesis of a number of inflammatory reactions and, consequently, inhibitors of inducible NO synthases may have therapeutic potential (4). fig. 1, d ), which is more lipophilic than the other arginine analogs and therefore is able to penetrate the cell membrane, and finally iii) N(co)-amino-L-arginine ( fig. 1 e) have been synthesized (5-7) as prototype arginine analogs. These N G -substituted L-arginine analogs have been extensively used to inhibit NO synthase activity in vitro and in vivo (5) , but their specificity is limited (8) .
In the guanidino group, the isosteric replacement of the terminal imine function by a sulphur atom gave rise to a new class of inhibitors including L-thiocitrulline (9) ( fig. 1, f) , while the replacement of the NH 2 function by a S-alkyl group led to compounds such as S-methyl ( fig. l,g ) or S-ethyl-L-isothiocitrulline ( fig. l,h ). The latter compounds are shown to be potent, reversible and slowbinding inhibitors of all NO synthases but are, respectively, 10-and 50-fold more potent inhibitors of neuronal than endothelial NO synthases (10).
It appears that the guanidine moiety of Ζ,-arginine -NH-C(=NH)-NH 2 is the pharmacophore group. This fact prompted the study of anti-NO synthase properties of non-amino acid based inhibitors ( fig. 2 ) such as aminoguanidine ( fig. 2, a) containing a hydrazine moiety that might confer selectivity for the inducible NO synthase (11) . The N,N'-l,3-diaminoguanidine compound ( fig.  2,b) , which appeared to be selective for inducible NO synthase (12) , seemed less potent than aminoguanidine. The most potent inhibitors of inducible NO synthase among the guanidino group seemed to be mercaptopropyl and mercaptoethylguanidine (13) (fig. 2,c) .
Among the N 5 N'-(alkane-l,o>-diyl) bis (guanidine) compounds, arcaine ( fig. 2, d ), the 1,4-diguanidino-butane exhibited a moderate inhibition of NO synthases (14) . In the -NH-C(=NH)-NH 2 guanidine moiety the secondary amine isosteric replacement by a sulfur atom gave rise to a new class of S-substituted isothiourea compounds called the ITU group R-S-C(=NH)-NH 2 , (fig. 2, e) which appeared to be strong inhibitors of NO syn-
thases (15) (16) (17) . S-ethyl-isothiourea and S-isopropylisothiourea seemed to be the most potent structures of the straight chain, while extension of the side chain R decreased the potency (n-propyl > i-butyl > «-butyl) (15) . Another isothiourea potent group was bis-isothiourea ( fig. 2, f) , in which sulphur atoms of two isothiourea units were linked by a carbon chain, containing eventually unsatured (hetero)cyclic rings. Some of these bis isothioureas showed marked selectivity for the human inducible NO synthase when compared to constitutive NO synthases. The bis-isothiourea, S,S'-(l,3-phenylenebis(l,2-ethanediyl)bis-isothiourea ( fig. 2,g ) was 190-fold more selective for the inducible NO synthase than for endothelial NO synthase (15) .
Guanidine and isothiourea can be classified as derivatives of amidine. The propionamidine compound (fig. 2, h) and longer chained amidines inhibited the inducible NO synthase (18) .
Here was examined the ability of some S,S'-(alkane-Ι,ω-diyl) bisisothiouronium dibromides and N,N'-(alkane-l,co-diyl) bisguanidinium dinitrates and the newly synthesized Ν,Ν'-bis (3-guanidinopropyl)piperazine dinitrate to inhibit, in the rat, NO generation in the course of an inflammatory reaction. Some of these compounds (bisisothiouronium salts) have already been tested in vitro, but not in vivo (15) . To our knowledge, the bisguanidinium salts were already synthesized but tested neither in vitro nor in vivo as NO synthase inhibitors.
We explored the potential selectivity of these agents towards constitutive and inducible isoforms of NO synthases in comparison to the activity of 2-methyl-2-thiopseudourea sulphate previously described as a potent NO synthase inhibitor by SOwi/ζα« et al. (16) and considered as the reference compound.
Material and Methods

Chemicals
Two S,S'-(alkane-l,a)-diyl) bisisothiouronium dibromides have been synthesized according to the method described by Garvey et al. (15) . 
Animals and treatments
Male Sprague-Dawley rats weighing 180-200 g (Depre, SaintDoulchard, France) were used for all experiments (20) . Protocols were submitted and approved by the local ethics committee.
Pleurisy was induced by intrapleural injection of 0.1 ml of 10 g/1 carrageenan λ suspension in saline (21).
The methyl 2-thiopseudourea sulphate, bisisothiouronium and bisguanidinium salts (0.1 ml) were administered with the inflammatory stimulus into the pleural cavity at concentrations varying from 5 X 10~6 to 10~4 mol/1.
Animals were euthanized with ether, and the right pleural cavity was opened for pleural exudate collection at 30 min (t = 0.5 h) or seven hours (t = 7 h). Samples were centrifuged at 500 g for 5 min, and the supernatants were then centrifuged at 1000 g for 20 min in order to remove exudate fibrin. Samples were then adjusted to a final volume of 1 ml with Hank's solution and stored at -80 °C until nitrite determination was carried out.
Nitrite determination in pleural exudate
Nitrite was measured in pleural exudates as an indicator of NO formation (22) . Aliquots of 0.1 ml were incubated in individual wells of a 96-well plate, with 0.1 ml of Griess reagent (0.5 g/l N-(l-naphthyl)-ethylenediamine and 5 g/1 sulphanilamide in phosphoric acid (50 g/1), at room temperature for 10 min. The absorbance was measured at 550 nm using a microplate reader (Dynatech, MRX), in comparison with the incubating medium (Hank's solution) without cells. Sodium nitrite was used to establish a nitrate standard curve.
Statistical analysis
The Mann-Whitney U test (in the computer program Statview II) was carried out in each group between treated and nontreated rats.
Results were given as a mean ± SEM. Differences with p < 0.05 were considered as significant.
Results
NO generation was assessed 0.5 and 7 hours after the induction of the inflammatory reaction. According to previous studies (23) this production correlated to the activation of constitutive and inducible NO synthases respectively.
In a first series of experiments, bisthiouronium salts at a dose of 5 X 10~5 mol/1 showed a similar inhibiting effect to that exerted by the same dose of the reference compound (2-methyl-2-thiopseudourea sulphate). This dose was chosen in accordance to previous studies (23) that demonstrated activity of this reference compound. S,S'-(octane-l,8-diyl) bisisothiouronium dibromide (compound I) was the major effective compound at 0.5 h and S,S'-(nonane-l,9-diyl) bisisothiouronium dibromide (compound II) at 7 h.
These results led us to examine the effect exerted by these compounds compared to the reference compound in a concentration range varying from 5 X 10 6 mol/1 and up to 10~4 mol/1 after the induction of pleurisy by carrageenan λ. Similar results were obtained with the three compounds at 0.5 h for the constitutive NO synthase ( fig. 3) . The inhibiting effect was most striking on nitrite generation measured 7 hours after the beginning of the inflammatory reaction and reflecting the inducible NO synthase stimulation. The dose of 5 X 10~5 mol/1 was the most effective for compound I. Compound II seemed to be a more potent inhibitor than compound I at 7 h, and quite similar to the reference compound at the three doses tested (fig. 4) . Figure 5 shows the effects produced by the bisguanidinium compounds (compounds III, IV, V), compound VI and the reference compound at 0.5 and 7 h after the induction of pleurisy. Results were significantly different from controls at 0.5 h, only with the N,N'(heptane-1,7-diyl) bisguanidinium dinitrate (compound IV) and N,N'-bis (3-guanidinopropyl) piperazine dinitrate (compound VI). At 7 h, all the results were significantly different from controls, with a major effect observed with compound IV and the reference compound.
Discussion
These bisisothiouronium and bisguanidinium salts demonstrated the inhibiting effect on NO generation in the course of carrageenan-induced pleurisy, as well as 2-methyl-2-thiopseudourea sulphate previously studied in vitro by Southan et al. (16) . Their activity is most significant against inducible rather than constitutive NO synthases. However, the specificity of the compounds in relation to the chain length and to the dose. No clear reason was found for the lack of dose-response relationship, even for the reference compound. In previous experiments, we have determined that 5 X 10~5 mol/1 of 2-methyl-2-thiopseudourea sulphate was sufficient for the inhibition of NO synthases, which was never complete even after administration of higher doses. Similar phenomenon could be observed with the bisthiouronium and bisguanidinium salts. The potential therapeutic role of NO synthase inhibitors depends on the importance of NO release in pathological situations (24) . The full therapeutic potential will be defined when NO protective functions are maintained and when only over-production (with potential proinflammatory properties) is decreased. Actually, potential therapeutic application of agents that modulate NO is emerging for the treatment of inflammatory disease, pulmonary hypertension, radioresistance of tumour cells, septic shock and vascular restenosis following angioplasty (25) .
